Global Bispecific Antibody Development Platform 麻豆原创 Research Report 2024

Publication ID:

PB512249423

Publication Date:

December 17, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Computing & Electronics [3]

Description:

The global market for Bispecific Antibody Development Platform was valued at US$ 934 million in the year 2023 and is projected to reach a revised size of US$ 1798 million by 2030, growing at a CAGR of 9.8% during the forecast period.
A Bispecific Antibody Development Platform is a specialized technological infrastructure that enables the creation and optimization of bispecific antibodies. It combines various advanced scientific techniques from molecular biology, protein engineering, and biotechnology. This platform allows for the design and production of antibodies capable of binding to two distinct targets simultaneously, which can be different antigens on the same cell or antigens on separate cells. Bispecific antibodies developed using such a platform hold significant potential in the field of medicine, as they can offer more targeted and complex therapeutic strategies compared to traditional monoclonal antibodies, for instance, by simultaneously engaging immune cells and disease-causing cells to enhance the effectiveness of treatments such as in cancer immunotherapy or autoimmune disease management.
North American market for Bispecific Antibody Development Platform is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Bispecific Antibody Development Platform is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Bispecific Antibody Development Platform in Pharmaceutical is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Bispecific Antibody Development Platform include KBI Biopharma, Genmab, Alloy Therapeutics, Inc., WuXi Biologics, Kyinno Biotechnology, The Jackson Laboratory, Numab Therapeutics AG, Compass Therapeutics, Inc., Charles River, Creative Biolabs, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Bispecific Antibody Development Platform, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bispecific Antibody Development Platform.
The Bispecific Antibody Development Platform market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bispecific Antibody Development Platform market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bispecific Antibody Development Platform companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
KBI Biopharma
Genmab
Alloy Therapeutics, Inc.
WuXi Biologics
Kyinno Biotechnology
The Jackson Laboratory
Numab Therapeutics AG
Compass Therapeutics, Inc.
Charles River
Creative Biolabs
invenra
Segment by Type
AI-based
Not AI-based
Segment by Application
Pharmaceutical
Biotechnology
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bispecific Antibody Development Platform company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Bispecific Antibody Development Platform 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 AI-based
1.2.3 Not AI-based
1.3 麻豆原创 by Application
1.3.1 Global Bispecific Antibody Development Platform 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pharmaceutical
1.3.3 Biotechnology
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Bispecific Antibody Development Platform 麻豆原创 Perspective (2019-2030)
2.2 Global Bispecific Antibody Development Platform Growth Trends by Region
2.2.1 Global Bispecific Antibody Development Platform 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Bispecific Antibody Development Platform Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Bispecific Antibody Development Platform Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Bispecific Antibody Development Platform 麻豆原创 Dynamics
2.3.1 Bispecific Antibody Development Platform Industry Trends
2.3.2 Bispecific Antibody Development Platform 麻豆原创 Drivers
2.3.3 Bispecific Antibody Development Platform 麻豆原创 Challenges
2.3.4 Bispecific Antibody Development Platform 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Bispecific Antibody Development Platform Players by Revenue
3.1.1 Global Top Bispecific Antibody Development Platform Players by Revenue (2019-2024)
3.1.2 Global Bispecific Antibody Development Platform Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Bispecific Antibody Development Platform 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Bispecific Antibody Development Platform Revenue
3.4 Global Bispecific Antibody Development Platform 麻豆原创 Concentration Ratio
3.4.1 Global Bispecific Antibody Development Platform 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bispecific Antibody Development Platform Revenue in 2023
3.5 Global Key Players of Bispecific Antibody Development Platform Head office and Area Served
3.6 Global Key Players of Bispecific Antibody Development Platform, Product and Application
3.7 Global Key Players of Bispecific Antibody Development Platform, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Bispecific Antibody Development Platform Breakdown Data by Type
4.1 Global Bispecific Antibody Development Platform Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Bispecific Antibody Development Platform Forecasted 麻豆原创 Size by Type (2025-2030)
5 Bispecific Antibody Development Platform Breakdown Data by Application
5.1 Global Bispecific Antibody Development Platform Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Bispecific Antibody Development Platform Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Bispecific Antibody Development Platform 麻豆原创 Size (2019-2030)
6.2 North America Bispecific Antibody Development Platform 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Bispecific Antibody Development Platform 麻豆原创 Size by Country (2019-2024)
6.4 North America Bispecific Antibody Development Platform 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Bispecific Antibody Development Platform 麻豆原创 Size (2019-2030)
7.2 Europe Bispecific Antibody Development Platform 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Bispecific Antibody Development Platform 麻豆原创 Size by Country (2019-2024)
7.4 Europe Bispecific Antibody Development Platform 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Bispecific Antibody Development Platform 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Bispecific Antibody Development Platform 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Bispecific Antibody Development Platform 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Bispecific Antibody Development Platform 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Bispecific Antibody Development Platform 麻豆原创 Size (2019-2030)
9.2 Latin America Bispecific Antibody Development Platform 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Bispecific Antibody Development Platform 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Bispecific Antibody Development Platform 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Bispecific Antibody Development Platform 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Bispecific Antibody Development Platform 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Bispecific Antibody Development Platform 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Bispecific Antibody Development Platform 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 KBI Biopharma
11.1.1 KBI Biopharma Company Details
11.1.2 KBI Biopharma Business Overview
11.1.3 KBI Biopharma Bispecific Antibody Development Platform Introduction
11.1.4 KBI Biopharma Revenue in Bispecific Antibody Development Platform Business (2019-2024)
11.1.5 KBI Biopharma Recent Development
11.2 Genmab
11.2.1 Genmab Company Details
11.2.2 Genmab Business Overview
11.2.3 Genmab Bispecific Antibody Development Platform Introduction
11.2.4 Genmab Revenue in Bispecific Antibody Development Platform Business (2019-2024)
11.2.5 Genmab Recent Development
11.3 Alloy Therapeutics, Inc.
11.3.1 Alloy Therapeutics, Inc. Company Details
11.3.2 Alloy Therapeutics, Inc. Business Overview
11.3.3 Alloy Therapeutics, Inc. Bispecific Antibody Development Platform Introduction
11.3.4 Alloy Therapeutics, Inc. Revenue in Bispecific Antibody Development Platform Business (2019-2024)
11.3.5 Alloy Therapeutics, Inc. Recent Development
11.4 WuXi Biologics
11.4.1 WuXi Biologics Company Details
11.4.2 WuXi Biologics Business Overview
11.4.3 WuXi Biologics Bispecific Antibody Development Platform Introduction
11.4.4 WuXi Biologics Revenue in Bispecific Antibody Development Platform Business (2019-2024)
11.4.5 WuXi Biologics Recent Development
11.5 Kyinno Biotechnology
11.5.1 Kyinno Biotechnology Company Details
11.5.2 Kyinno Biotechnology Business Overview
11.5.3 Kyinno Biotechnology Bispecific Antibody Development Platform Introduction
11.5.4 Kyinno Biotechnology Revenue in Bispecific Antibody Development Platform Business (2019-2024)
11.5.5 Kyinno Biotechnology Recent Development
11.6 The Jackson Laboratory
11.6.1 The Jackson Laboratory Company Details
11.6.2 The Jackson Laboratory Business Overview
11.6.3 The Jackson Laboratory Bispecific Antibody Development Platform Introduction
11.6.4 The Jackson Laboratory Revenue in Bispecific Antibody Development Platform Business (2019-2024)
11.6.5 The Jackson Laboratory Recent Development
11.7 Numab Therapeutics AG
11.7.1 Numab Therapeutics AG Company Details
11.7.2 Numab Therapeutics AG Business Overview
11.7.3 Numab Therapeutics AG Bispecific Antibody Development Platform Introduction
11.7.4 Numab Therapeutics AG Revenue in Bispecific Antibody Development Platform Business (2019-2024)
11.7.5 Numab Therapeutics AG Recent Development
11.8 Compass Therapeutics, Inc.
11.8.1 Compass Therapeutics, Inc. Company Details
11.8.2 Compass Therapeutics, Inc. Business Overview
11.8.3 Compass Therapeutics, Inc. Bispecific Antibody Development Platform Introduction
11.8.4 Compass Therapeutics, Inc. Revenue in Bispecific Antibody Development Platform Business (2019-2024)
11.8.5 Compass Therapeutics, Inc. Recent Development
11.9 Charles River
11.9.1 Charles River Company Details
11.9.2 Charles River Business Overview
11.9.3 Charles River Bispecific Antibody Development Platform Introduction
11.9.4 Charles River Revenue in Bispecific Antibody Development Platform Business (2019-2024)
11.9.5 Charles River Recent Development
11.10 Creative Biolabs
11.10.1 Creative Biolabs Company Details
11.10.2 Creative Biolabs Business Overview
11.10.3 Creative Biolabs Bispecific Antibody Development Platform Introduction
11.10.4 Creative Biolabs Revenue in Bispecific Antibody Development Platform Business (2019-2024)
11.10.5 Creative Biolabs Recent Development
11.11 invenra
11.11.1 invenra Company Details
11.11.2 invenra Business Overview
11.11.3 invenra Bispecific Antibody Development Platform Introduction
11.11.4 invenra Revenue in Bispecific Antibody Development Platform Business (2019-2024)
11.11.5 invenra Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

KBI Biopharma
Genmab
Alloy Therapeutics, Inc.
WuXi Biologics
Kyinno Biotechnology
The Jackson Laboratory
Numab Therapeutics AG
Compass Therapeutics, Inc.
Charles River
Creative Biolabs
invenra

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.